MX2017015297A - Metodos para reducir o prevenir daño a la intima provocado por estimulacion mecanica de celulas endoteliales. - Google Patents

Metodos para reducir o prevenir daño a la intima provocado por estimulacion mecanica de celulas endoteliales.

Info

Publication number
MX2017015297A
MX2017015297A MX2017015297A MX2017015297A MX2017015297A MX 2017015297 A MX2017015297 A MX 2017015297A MX 2017015297 A MX2017015297 A MX 2017015297A MX 2017015297 A MX2017015297 A MX 2017015297A MX 2017015297 A MX2017015297 A MX 2017015297A
Authority
MX
Mexico
Prior art keywords
mechanical stimulation
endothelial cells
damage caused
methods
reducing
Prior art date
Application number
MX2017015297A
Other languages
English (en)
Inventor
Jacobson Sven
Marc Simard J
Original Assignee
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland filed Critical Univ Maryland
Publication of MX2017015297A publication Critical patent/MX2017015297A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M25/104—Balloon catheters used for angioplasty
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Modalidades de la descripción abarcan métodos y/o composiciones para mejorar o prevenir daño a la íntima provocado por estimulación mecánica de células endoteliales. El daño puede ser provocado mediante el uso de un dispositivo dentro de una arteria, vena o capilar de un individuo, tal como para remover un trombo, un émbolo o una placa aterosclerótica en el vaso. Modalidades de tratamiento y prevención conciernen a cantidades terapéuticamente efectivas de uno o más antagonistas del canal SUR1 - TRPM4 que es sobrerregulado sobre la estimulación mecánica.
MX2017015297A 2015-05-29 2016-05-25 Metodos para reducir o prevenir daño a la intima provocado por estimulacion mecanica de celulas endoteliales. MX2017015297A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562168589P 2015-05-29 2015-05-29
PCT/US2016/034066 WO2016196113A1 (en) 2015-05-29 2016-05-25 Methods of reducing or preventing intimal damage caused by mechanical stimulation of endothelial cells

Publications (1)

Publication Number Publication Date
MX2017015297A true MX2017015297A (es) 2018-06-19

Family

ID=57441652

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017015297A MX2017015297A (es) 2015-05-29 2016-05-25 Metodos para reducir o prevenir daño a la intima provocado por estimulacion mecanica de celulas endoteliales.

Country Status (14)

Country Link
US (1) US10900040B2 (es)
EP (1) EP3302514B1 (es)
JP (2) JP6973752B2 (es)
KR (1) KR102618123B1 (es)
CN (1) CN108348567B (es)
AU (1) AU2016271576B2 (es)
CA (1) CA2988417C (es)
EA (1) EA038398B1 (es)
ES (1) ES2927482T3 (es)
HK (1) HK1252532A1 (es)
IL (1) IL255875A (es)
MA (1) MA45307A (es)
MX (1) MX2017015297A (es)
WO (1) WO2016196113A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2872012C (en) 2012-05-08 2017-06-20 Aeromics, Llc New methods
SG11201604153UA (en) 2013-11-06 2016-07-28 Aeromics Inc Novel formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2295195C (en) * 1997-06-18 2009-12-15 Discovery Therapeutics, Inc. Compositions and methods for preventing restenosis following revascularization procedures
JP5307397B2 (ja) * 2004-09-18 2013-10-02 ユニバーシティ オブ メリーランド，ボルチモア ＮＣＣａ−ＡＴＰチャネルを標的とする治療剤およびその使用方法
EP2114160B1 (en) * 2007-02-09 2016-11-16 University of Maryland, Baltimore Antagonists of a non-selective cation channel in neural cells
US8557867B2 (en) 2007-06-22 2013-10-15 The United States Of America As Represented By The Department Of Veterans Affairs Inhibitors of NCCa-ATP channels for therapy
PT2868315T (pt) 2007-12-04 2017-09-04 Remedy Pharmaceuticals Inc Formulações melhoradas e métodos para liofilização e liofilizados assim produzidos
CN109172363A (zh) 2010-07-19 2019-01-11 比根切萨彼公司 静脉内施用格列苯脲和其他药物的方法

Also Published As

Publication number Publication date
US20180155727A1 (en) 2018-06-07
HK1252532A1 (zh) 2019-05-31
KR20180035741A (ko) 2018-04-06
EA201792569A1 (ru) 2018-04-30
EP3302514A1 (en) 2018-04-11
CA2988417A1 (en) 2016-12-08
AU2016271576B2 (en) 2021-10-07
KR102618123B1 (ko) 2023-12-27
EP3302514B1 (en) 2022-07-06
EA038398B1 (ru) 2021-08-23
WO2016196113A1 (en) 2016-12-08
JP2021167335A (ja) 2021-10-21
JP6973752B2 (ja) 2021-12-01
EP3302514A4 (en) 2019-04-24
CN108348567A (zh) 2018-07-31
ES2927482T3 (es) 2022-11-07
JP2018516981A (ja) 2018-06-28
US10900040B2 (en) 2021-01-26
MA45307A (fr) 2018-04-11
CA2988417C (en) 2022-10-11
AU2016271576A1 (en) 2018-01-04
CN108348567B (zh) 2022-03-01
IL255875A (en) 2018-01-31

Similar Documents

Publication Publication Date Title
IL273824A (en) Methods of using ehmt2 inhibitors in the treatment or prevention of blood disorders
MX2022007472A (es) Uso de plinabulina en combinacion con inhibidores de punto de control inmunitario.
ZA202208792B (en) Methods of treating and preventing graft versus host disease
MX2017000307A (es) Tratamiento de leucemia con inhibidores de histona deacetilasa.
GT201700134A (es) Inhibidores de erk
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
MA40437A (fr) Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
MX2021010528A (es) Metodos y composiciones para el tratamiento de las ulceras.
CR20160308A (es) Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores
MD4801B1 (ro) Antagonişti ai activin-ActRII şi utilizarea lor pentru tratamentul sindroamelor mielodisplazice
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
MX369691B (es) Inhibidores de glutaminasa y métodos de empleo.
MY184106A (en) Treatment of dna damage and mitochondrial dysfunction using palm fruit juice
TR201900319T4 (tr) C1 esteraz inhibitör eksikliği ile ilişkili bozuklukların önlenmesinde ve tedavisinde kullanım için c1-inh bileşimleri ve yöntemler.
PH12016502291A1 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
PH12017501980A1 (en) The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc)
MX2017006019A (es) Apilimod para uso en el tratamiento de melanoma.
MX2016016793A (es) Discos de aireacion y metodos para usar los mismos.
MX2017015297A (es) Metodos para reducir o prevenir daño a la intima provocado por estimulacion mecanica de celulas endoteliales.
NZ724799A (en) Compositions and methods for the treatment or prevention of neurodegenerative disorders
MX2017003020A (es) Compuestos de dipeptidil-cetoamida y su uso para el tratamiento y/o la prevencion de la acumulacion de grasa.
HK1246205A1 (zh) 在預防和/或治療皮膚損傷中使用的至少一種蛋白酶抑制劑和至少一種活性成分的組合
IL247616B (en) Centrally acting acetylcholinesterase inhibitors for the prevention/or treatment of chemically induced neurodegenerative diseases and their symptoms, and corresponding compositions, uses, methods and kit